Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in non-del 5q MDS
NCT01029262Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Jan 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01029262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029262.